Attenuation of insulin’s glucose-lowering action in vivo, termed “insulin resistance,” commonly develops as a maladaptive response to obesity and is widely viewed as a critical mediator of the link between obesity and pandemic disorders, including type 2 diabetes, fatty liver, dyslipidemia, subfertility, and cancer. Here, INS is linked to metabolic syndrome.